Testosterone TEPI Patch® for Women
Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women
Phase 1Active
Key Facts
Indication
Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women
Phase
Phase 1
Status
Active
Company
About Medherant
Medherant is a UK-based, clinical-stage biotech focused on advancing transdermal drug delivery via its proprietary TEPI Patch® technology. Founded in 2014 with roots in University of Warwick polymer chemistry, the company is developing its own pipeline, starting with a testosterone patch for women's health, and offers a collaborative platform for partners. Having completed a positive Phase 1 trial for its lead asset, Medherant is positioned to address significant unmet needs in hormone therapy and pain management with a potentially superior patch format.
View full company profile